Big Splash Acquisitions Could Drive Investors Toward Biotech
This article was originally published in The Pink Sheet Daily
Regulatory setbacks have spooked public market investors, but recent deals could spark return, according to BioInvestor Forum panelists.
You may also be interested in...
Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.
$2.1 bil. deal will allow Lilly to benefit from efficiencies in development, marketing and sales of the erectile dysfunction product.
The $2.5 bil. deal will add a late-stage candidate, ambrisentan, for the treatment of pulmonary arterial hypertension to Gilead's pipeline.